Campbell & CO Investment Adviser LLC Eagle Pharmaceuticals, Inc. Transaction History

Campbell & CO Investment Adviser LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$25.06 - $34.09 $356,578 - $485,066	-14,229 Reduced 63.11%	8,318 $235,000
Q4 2022 Feb 14, 2023	SELL	$24.98 - $39.77 $628,996 - $1 Million	-25,180 Reduced 52.76%	22,547 $659,000
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $1.13 Million - $2.02 Million	42,840 Added 876.61%	47,727 $1.26 Million
Q2 2022 Aug 09, 2022	SELL	$41.26 - $51.35 $120,190 - $149,582	-2,913 Reduced 37.35%	4,887 $217,000
Q1 2022 May 09, 2022	BUY	$44.58 - $52.6 $347,724 - $410,280	7,800 New	7,800 $386,000
Q1 2019 May 10, 2019	SELL	$38.66 - $51.82 $289,486 - $388,028	-7,488 Closed	0 $0
Q4 2018 Feb 08, 2019	BUY	$36.72 - $67.73 $91,359 - $168,512	2,488 Added 49.76%	7,488 $334,000
Q3 2018 Nov 08, 2018	BUY	$66.65 - $83.86 $333,250 - $419,300	5,000 New	5,000 $347,000
Q1 2018 May 04, 2018	SELL	$52.16 - $66.86 $220,010 - $282,015	-4,218 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$49.6 - $60.87 $209,212 - $256,749	4,218	4,218 $225,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.